In Vitro Safety and Pharmacology
IMPROVING YOUR SAFETY AND
EFFICACY RESPONSES IN VITRO
Our assays and services enable toxicologists and pharmacologists to gain insights on the mechanisms of renal drug-to-drug effects and toxic responses.
Using iPSC technology, we generate cell based assays from control human and other pre-clinical species for safety studies in difficult to obtain cells and tissues such as neurons, retina, skin, cochlea and lung.
Our platform for renal studies provides cross-species data on renal clearance and nephrotoxicity in a high-throughput format, where we can also provide a complete study design service.
The location and physiological structure of the human eye makes it vulnerable to damage from hazardous chemicals and a range of drugs have demonstrated toxicity to the retina and other ocular structures. There is an unmet need for an in vitro model of the human retina that is capable of high-content screening of drugs for toxicity effects. Using iPSC technology, Newcells Biotech is collaborating with major pharmaceutical companies to develop an assay using retinal organoids. We have shown that these organoids contain all the major cell types found in vivo and are electrically active in response to light. Initial studies with known toxins show effects similar to that seen in vivo. For more information on the development of our retina assay please contact us.
The skin is an important barrier that protects and regulates the exposure of the body to xenobiotics. This tissue is also metabolically active and can activate and detoxify topically applied drugs and chemicals. Understanding the pathways of metabolism in skin is critical to determining local and systemic toxicity and currently there are limited in vitro assays capable of providing this data. Newcells is developing in collaboration with major pharmaceutical and consumer goods companies an iPSC-based full thickness model of human skin. The model contains in addition to keratinocytes and fibroblasts other cell types found in skin making it a closer model to in vivo skin tissue. In parallel with the in vitro model we are developing an in silico model of skin metabolism that together will provide complementary tools for assessing skin metabolism of xenobiotics. For more information on our skin assay capability please contact us.
Kidney damage accounts for up to 20% of failures during the drug development pathway. The major roadblock to reducing drug attrition during development is the poorly predictive nature of current animal based screening models. To address this issue we developed highly differentiated cell culture models of the human, rat and other species kidney proximal tubule (aProximateTM cells), which recapitulate the physiology of the in vivo proximal tubule and when allied to a broad screen of toxicity, provide mechanistic and species-specific data about the nephrotoxic potential of NCEs. Compared to other assays aProximateTM expresses the key drug transporters at significantly higher levels. The assay service provided by Newcells Biotech provides data on total flux, potential drug-drug interactions as well as nephrotoxicity assessment using biomarkers such as KIM-1, NGAL and clusterin. Newcells Biotech provides a comprehensive work study design and consultation with our consultant Dr Colin Brown, a world expert in transport proteins. For detailed information on the aProximateTM assay please contact us.
Accelerate your pre-clinical testing
Sign-up to our newsletter for the latest information about our work and projects.